Bristol-Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for ORENCIA® (abatacept) to Help Prevent Acute Graft-Versus-Host Disease, a Potentially Life-Threatening Complication After Stem Cell Transplant  West Plains Daily Quill

Bristol-Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for ORENCIA® (abatacept) to Help Prevent Acute Graft-Versus-Host Disease, a Potentially Life-Threatening Complication After Stem Cell Transplant  Business Wire

What’s Going On Dec. 4  Odessa American

93 People In North Yorkshire On Organ Transplant Waiting List  Yorkshire Coast Radio

Prominent Political Donors Charged in Campaign Finance Scheme  The New York Times

Doctors Restart a Heart for Transplant After Removing from a Dead Donor  Tech Times